AU2003279924A1 - Therapeutic combination of carnitine and antioxidant polyphenols - Google Patents

Therapeutic combination of carnitine and antioxidant polyphenols Download PDF

Info

Publication number
AU2003279924A1
AU2003279924A1 AU2003279924A AU2003279924A AU2003279924A1 AU 2003279924 A1 AU2003279924 A1 AU 2003279924A1 AU 2003279924 A AU2003279924 A AU 2003279924A AU 2003279924 A AU2003279924 A AU 2003279924A AU 2003279924 A1 AU2003279924 A1 AU 2003279924A1
Authority
AU
Australia
Prior art keywords
carnitine
acid
composition
hydroxytyrosol
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003279924A
Other languages
English (en)
Inventor
Roberto Crea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creagri Inc
Original Assignee
Creagri Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creagri Inc filed Critical Creagri Inc
Publication of AU2003279924A1 publication Critical patent/AU2003279924A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
AU2003279924A 2002-10-11 2003-10-10 Therapeutic combination of carnitine and antioxidant polyphenols Abandoned AU2003279924A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41783802P 2002-10-11 2002-10-11
US60/417,838 2002-10-11
PCT/US2003/032149 WO2004032873A2 (en) 2002-10-11 2003-10-10 Therapeutic combination of carnitine and antioxidant polyphenols

Publications (1)

Publication Number Publication Date
AU2003279924A1 true AU2003279924A1 (en) 2004-05-04

Family

ID=32094102

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003279924A Abandoned AU2003279924A1 (en) 2002-10-11 2003-10-10 Therapeutic combination of carnitine and antioxidant polyphenols

Country Status (6)

Country Link
US (1) US20040132821A1 (enExample)
EP (1) EP1558199A4 (enExample)
JP (1) JP2006506361A (enExample)
AU (1) AU2003279924A1 (enExample)
CA (1) CA2531056A1 (enExample)
WO (1) WO2004032873A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115283B2 (en) * 2003-05-06 2006-10-03 Access Business Group International Llc Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals
JP4954450B2 (ja) * 2004-06-14 2012-06-13 ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス 弾性繊維形成の不全、欠損又は無秩序による病状に対処するための、リシルオキシダーゼのアイソフォームの活性の誘導
WO2006053872A1 (en) * 2004-11-16 2006-05-26 Dsm Ip Assets B.V. The use of anti-oxidant compounds for muscle recovery
JP5685362B2 (ja) * 2005-04-26 2015-03-18 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン
ES2261088B1 (es) * 2005-04-27 2007-12-01 Laboratorios Alcala Farma, S.L. Uso de hidroxitirosol en la prevencion y tratamiento del ictus cerebral isquemico.
RU2304964C2 (ru) * 2005-09-26 2007-08-27 Общество с ограниченной ответственностью "Экофарминвест" Способ лечения хронической сердечной недостаточности
US20090163579A1 (en) * 2005-10-14 2009-06-25 Daniel Raederstorff Novel use of nutraceutical compositions
US20070231371A1 (en) 2006-02-01 2007-10-04 Nestec, S. A. Nutritional system and methods for increasing longevity
JP2007330191A (ja) * 2006-06-16 2007-12-27 Nihon Yobo Igaku Kenkyusho:Kk メイラード反応を抑制する食品
IT1391928B1 (it) * 2008-08-29 2012-02-02 Giellepi Chemicals S P A Integratore alimentare per il trattamento di neuropatie
PL2418965T3 (pl) 2009-04-17 2016-12-30 Połączenia hydroksytyrozolu do zwiększania czynności mitochondrium i wytwarzania energii
US8796315B2 (en) 2009-06-25 2014-08-05 Darlene E. McCord Methods for improved wound closure employing olivamine and human umbilical vein endothelial cells
US8809311B2 (en) 2009-08-10 2014-08-19 Darlene McCord Nutritional supplements
EP2445483B1 (en) 2009-06-25 2017-04-26 McCord, Darlene Topical compositions and methods for wound care
WO2011109525A1 (en) * 2010-03-02 2011-09-09 Nox Technologies, Inc. Aging-Related Circulating Particle-Associated Lipoprotein B Oxidase (apoBNOX) and Inhibitors Thereof
WO2014085613A1 (en) 2012-11-30 2014-06-05 Mccord Darlene E Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
EP3706759B1 (en) * 2017-11-08 2023-11-15 Société des Produits Nestlé S.A. Homovanillyl alcohol (hva), hva isomer, methods of making compositions comprising such compounds, and methods using such compounds
CN113615833A (zh) * 2021-07-01 2021-11-09 泓博元生命科技（深圳）有限公司 一种用于改善心血管的线粒体营养素组合物及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002041A1 (en) * 1995-07-03 1997-01-23 Crandall Wilson T Transdermal and oral treatment of androgenic alopecia
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
US5667791A (en) * 1996-05-31 1997-09-16 Thione International, Inc. X-ray induced skin damage protective composition
US6337320B1 (en) * 1996-10-11 2002-01-08 Thione International, Inc. Reparatives for ultraviolet radiation skin damage
DE19824346A1 (de) * 1998-06-02 1999-12-09 Peter Schleicher Nahrungsergänzungsmittel
IT1299197B1 (it) * 1998-06-30 2000-02-29 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante, antiproliferativa, energetica e atta a migliorare l'utilizzazione metabolica del glucosio.
IT1302307B1 (it) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
AU2280900A (en) * 1998-12-22 2000-07-12 Unilever Plc Food compositions fortified with anti-oxidants
WO2001076579A1 (en) * 2000-04-06 2001-10-18 Perricone Nicholas V Treatment of skin damage using olive oil polyphenols
IT1317036B1 (it) * 2000-05-30 2003-05-26 Sigma Tau Healthscience Spa Integratore ad attivita' antiossidante comprendente unaalcanoilcarnitina ed una associazione di polifenoli estratti da piante
PT1315691E (pt) * 2000-09-01 2012-11-22 Creagri Inc Método para obter uma composição rica em hidroxitirosol a partir de água de vegetação

Also Published As

Publication number Publication date
JP2006506361A (ja) 2006-02-23
US20040132821A1 (en) 2004-07-08
WO2004032873A3 (en) 2004-07-29
CA2531056A1 (en) 2004-04-22
WO2004032873A2 (en) 2004-04-22
EP1558199A4 (en) 2006-06-28
EP1558199A2 (en) 2005-08-03

Similar Documents

Publication Publication Date Title
CA2341973C (en) Antioxidant composition comprising acetyl l-carnitine and .alpha.-lipoic acid
US20040132821A1 (en) Therapeutic combination of carnitine and antioxidant polyphenols
Hayashi et al. Effect of astaxanthin-rich extract derived from Paracoccus carotinifaciens on cognitive function in middle-aged and older individuals
CA2344893C (en) Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders
KR20200040276A (ko) 신경 손상 치료를 위한 아미노산 조성물
US8318954B2 (en) Cleavable carnitine compound
ITRM980433A1 (it) Composizione ad attivita' antiossidante antiproliferativa energetica e atta a migliorare l'utilizzazione metabolica del glucosio
WO2006015774A1 (de) Physiologisch verträgliche zusammensetzung enthaltend alphaliponsaüre, kreatin und ein phospholipid
US20210308081A1 (en) Method and Composition for Enhancing the Quality and Benefits of Sleep
EP0428608A1 (fr) Compositions pharmaceutiques et/ou dietetiques contenant de la l-carnitine et de la l-lysine
CA3195029A1 (en) Methods for improving exercise performance and endurance thereof
MXPA01002045A (en) ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND&agr;-LIPOIC ACID
JP5079503B2 (ja) ラジカルスカベンジャー及び活性酸素消去剤
WO2006042666A1 (de) R-(+)-α-LIPONSÄURE ZUR PRÄVENTION VON DIABETES
WO2008037047A1 (en) Composition and method for increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance
MXPA01003569A (es) Combinacion de carnitinas y resveratrol para prevenir o tratar enfermedades cerebrales y del envejecimiento

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period